CBMTG is happy to provide webinars free of charge to members of the Society!
If you are a member, please be sure to login with your username and password before registering for this webinar.
Non-Members: $90 plus tax
Wednesday, March 6, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0
Current Management of Waldenstrom Macroglobulinemia
Jorge J. Castillo, MD (Dana-Farber Cancer Institute, Boston, Massachusetts)
Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. In 2013, Dr. Castillo was appointed Assistant Professor at Harvard Medical School. Dr. Castillo is the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute, and he sees approximately 1,000 patients with Waldenström Macroglobulinemia per year in his Clinic. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 200 peer-reviewed articles, and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.
1. Discuss the biology and pathogenesis of Waldenstrom macroglobulinemia
2. Review clinicopathological features of Waldenstrom macroglobulinemia
3. Provide an update treatment options in Waldenstrom macroglobulinemia, including the role of transplantation